Palvella Therapeutics (PVLA) Price & Analysis

Compare

647 Followers

PVLA Stock Chart & Stats

Day’s Range― - ―

52-Week Range$11.17 - $58.22

Previous CloseN/A

Volume11.83K

Average Volume (3M)138.88K

Market Cap

$598.77M

Enterprise Value$193.21M

Total Cash (Recent Filing)$70.43M

Total Debt (Recent Filing)$0.00

Price to Earnings (P/E)―

Beta0.24

Next Earnings

Apr 06, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.86

Shares Outstanding11,059,665

10 Day Avg. Volume109,739

30 Day Avg. Volume138,879

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.32

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/Ebitda-12.81

Forecast

1Y Price Target

$64.00

Price Target Upside14.94% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering10

Bulls Say, Bears Say

Bulls Say

Clinical TrialsEnrollment for the Phase 3 SELVA trial exceeded the original target by more than 25%, demonstrating strong interest and participation.

Financial OutlookThe company has more than two years of cash runway, indicating financial stability to support ongoing operations and development.

Product DevelopmentQTORIN rapamycin gives strong precedent data of clinical benefit, with statistically significant clinical improvement from baseline in 4 weeks of treatment.

Bears Say

Financial PerformancePalvella Therapeutics, Inc. reported a net loss of approximately $9.5M in the second quarter of 2025.

Operational CostsManagement has reiterated guidance for a cash burn of approximately $30M for the fiscal year 2025, indicating controlled financial management.

Palvella Therapeutics News

Palvella Therapeutics appoints Osborne as Chief Innovation Officer

Palvella Therapeutics (PVLA) announced the appointment of David Osborne, Ph.D. as Chief Innovation Officer, effective immediately. Dr. Osborne...

4d ago

PVLA

Palvella Therapeutics price target raised to $66 from $52 at Canaccord

Canaccord raised the firm’s price target on Palvella Therapeutics (PVLA) to $66 from $52 and keeps a Buy...

19d ago

PVLA

Palvella Therapeutics price target raised to $75 from $38 at H.C. Wainwright

H.C. Wainwright analyst Andres Maldonado raised the firm’s price target on Palvella Therapeutics (PVLA) to $75 from $38...

23d ago

PVLA

Palvella Therapeutics price target raised to $60 from $50 at Chardan

Chardan raised the firm’s price target on Palvella Therapeutics (PVLA) to $60 from $50 and keeps a Buy...

23d ago

PVLA

Palvella Therapeutics price target raised to $60 from $45 at Stifel

Stifel raised the firm’s price target on Palvella Therapeutics (PVLA) to $60 from $45 and keeps a Buy...

23d ago

PVLA

Palvella Therapeutics reports Q2 EPS (86c), consensus (77c)

“In the second quarter of 2025, we continued to advance Palvella’s mission of pioneering first-in-disease therapies for individuals...

24d ago

PVLA

Palvella Therapeutics Accelerates U.S. Launch Planning

Palvella Therapeutics ( ($PVLA) ) has issued an announcement. On September 3, 2025, Palvella Therapeutics released a corporate...

4d ago

PVLA

Palvella Therapeutics Advances Rare Disease Pipeline

Palvella Therapeutics, Inc. ( ($PVLA) ) has released its Q2 earnings. Here is a breakdown of the information...

23d ago

PVLA

Palvella Therapeutics: Strong Financial Position and Clinical Progress Justify Buy Rating with Raised Price Target

Analyst Ritu Baral from TD Cowen maintained a Buy rating on Palvella Therapeutics and increased the price target...

23d ago

PVLA

Positive Buy Rating for Palvella Therapeutics Driven by Promising Phase 3 Trial Developments and Market Potential

Palvella Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Sam Slutsky from...

23d ago

PVLA

Palvella Completes Enrollment in Phase 3 SELVA Trial

Palvella Therapeutics ( ($PVLA) ) has issued an update. Palvella Therapeutics reported its second quarter 2025 financial results...

24d ago

PVLA

Snap downgraded, Leidos upgraded: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here...

1M ago

ALC

Palvella Therapeutics initiated with an Outperform at Raymond James

Raymond James initiated coverage of Palvella Therapeutics (PVLA) with an Outperform rating and $54 price target Palvella is...

1M ago

PVLA

Palvella Therapeutics initiated with an Outperform at Raymond James

Raymond James initiated coverage of Palvella Therapeutics (PVLA) with an Outperform rating and $54 price target The firm...

1M ago

PVLA

PVLA FAQ

What was Palvella Therapeutics’s price range in the past 12 months?

Palvella Therapeutics lowest stock price was $11.17 and its highest was $58.22 in the past 12 months.

What is Palvella Therapeutics’s market cap?

Palvella Therapeutics’s market cap is $598.77M.

When is Palvella Therapeutics’s upcoming earnings report date?

Palvella Therapeutics’s upcoming earnings report date is Apr 06, 2026 which is in 211 days.

How were Palvella Therapeutics’s earnings last quarter?

Palvella Therapeutics released its earnings results on Aug 14, 2025. The company reported -$0.86 earnings per share for the quarter, missing the consensus estimate of -$0.741 by -$0.119.

Is Palvella Therapeutics overvalued?

According to Wall Street analysts Palvella Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Palvella Therapeutics pay dividends?

Palvella Therapeutics does not currently pay dividends.

What is Palvella Therapeutics’s EPS estimate?

Palvella Therapeutics’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Palvella Therapeutics have?

Palvella Therapeutics has 11,059,665 shares outstanding.

What happened to Palvella Therapeutics’s price movement after its last earnings report?

Palvella Therapeutics reported an EPS of -$0.86 in its last earnings report, missing expectations of -$0.741. Following the earnings report the stock price went up 3.271%.

Which hedge fund is a major shareholder of Palvella Therapeutics?

Currently, no hedge funds are holding shares in PVLA

Palvella Therapeutics Stock Smart Score

Outperform

Fundamentals

Return on Equity

-68.21%

Trailing 12-Months

Asset Growth

194.39%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Palvella Therapeutics

Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. Its lead product candidate is QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin) that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of other mTOR-driven skin diseases. The company is based in Wayne, Pennsylvania.

Palvella Therapeutics (PVLA) Earnings & Revenues

Historic Earnings Reports

PVLA Company Deck

PVLA Earnings Call

Q2 2025

0:00 / 0:00

PVLA Stock 12 Month Forecast

Average Price Target

$64.00

▲(14.94% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"11":"$11","103":"$103","195":"$195","287":"$287","379":"$379"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":90,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$90.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":64,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$64.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":50,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$50.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[11,103,195,287,379],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,36.55,40.661538461538456,44.77307692307692,48.88461538461539,52.996153846153845,57.107692307692304,61.21923076923077,65.33076923076923,69.4423076923077,73.55384615384615,77.66538461538462,81.77692307692308,85.88846153846154,{"y":90,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,36.55,38.661538461538456,40.77307692307692,42.88461538461538,44.996153846153845,47.107692307692304,49.21923076923076,51.33076923076923,53.44230769230769,55.55384615384615,57.66538461538461,59.776923076923076,61.888461538461534,{"y":64,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,36.55,37.58461538461538,38.61923076923077,39.65384615384615,40.68846153846154,41.723076923076924,42.75769230769231,43.79230769230769,44.82692307692308,45.86153846153846,46.89615384615385,47.93076923076923,48.965384615384615,{"y":50,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":281.6,"date":1627776000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":378.4,"date":1635724800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":302.4,"date":1640995200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.3,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.43,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.37,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.59,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.09,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.14,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.67,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.55,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >